Starpharma Holdings Limited (AU:SPL)
ASX:SPL
Want to see AU:SPL full AI Analyst Report?
SPL Stock Chart & Stats
AU$0.38
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.38
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.79
Previous CloseN/A
Volume337.59K
Average Volume (3M)724.95K
Market Cap
AU$282.02M
Enterprise ValueAU$277.19M
Total Cash (Recent Filing)AU$18.25M
Total Debt (Recent Filing)AU$790.00K
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding420,928,440
10 Day Avg. Volume366,126
30 Day Avg. Volume724,950
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)1.93
Price to Sales (P/S)7.47
P/FCF Ratio-5.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Platform & Diversified RevenueStarpharma’s proprietary dendrimer platform provides a structural competitive advantage, enabling multiple product applications and revenue streams (licensing, milestones, royalties, product sales). This diversification reduces single-product dependency and supports durable partner-driven commercialization channels over years.
Positive Revenue Growth MomentumSustained top-line growth demonstrates commercial traction for products or partner programs and underpins future scale. Over a 2–6 month horizon, continued revenue expansion supports potential operating leverage and validates the underlying technology’s market adoption independent of short-term market moves.
Conservative Balance Sheet And Capital StructureLow leverage and a healthy equity ratio give Starpharma financial flexibility to fund R&D and partnerships without immediate refinancing pressure. This conservatively structured balance sheet reduces solvency risk during biotech cycles and supports multi-period investment in development programs.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow constrains the company’s ability to internally fund R&D, scale commercialization, or absorb setbacks. Declining FCF growth increases reliance on external financing, raising dilution risk and limiting durable self-funded expansion over the medium term.
Ongoing Unprofitability And Weak ReturnsNegative EBIT and net margins indicate structural cost or commercialization inefficiencies that impair long-term earnings power. Without sustained margin improvement, the firm’s negative returns will continue to erode capital efficiency and prevent the business from generating durable shareholder value.
Reliance On Partners For CommercializationA business model reliant on licensing and partner commercialization creates revenue timing risk and caps capture of product economics. Partner-dependent commercialization can produce lumpy income and limits Starpharma’s ability to fully translate platform value into sustained, predictable margins and cash flow.
Starpharma Holdings Limited News
SPL FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.08 and its highest was AU$0.79 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is AU$282.02M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 74 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 420,928,440 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in AU:SPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
355.55%
12-Months-Change
Fundamentals
Return on Equity
-15.96%
Trailing 12-Months
Asset Growth
-4.84%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---